Zeo ScientifiX, Inc. reported a revenue increase of 12.5% for the fiscal year ending October 31, 2025, generating $5.2 million compared to $4.6 million in the previous year. The growth was primarily driven by the company's Patient Pure X™ (PPX™) service platform, which saw a revenue increase of 149% to $1.5 million. However, sales from higher concentration allogenic aesthetic biologic products decreased by 10.3%, reflecting increased competition in the market. The company incurred a net loss of $5.5 million, up from a loss of $4.7 million in the prior year, contributing to an accumulated deficit of $67.7 million.
In terms of operational developments, Zeo's customer base has expanded, with the company actively pursuing compliance with Florida's new stem cell therapy law, SB 1768, effective July 1, 2025. This legislation is expected to create significant demand for Zeo's products, allowing the company to market and sell its biologics more effectively. The company has also initiated a clinical study to evaluate the safety and efficacy of PPX™ in patients with musculoskeletal joint pathologies, with plans to enroll up to 350 patients.
Strategically, Zeo completed the acquisition of BioLumina, LLC on June 25, 2025, for $200,000, which included finished goods inventory and pending trademark applications. The company also entered into a joint venture with BioXtek, although this partnership faced legal challenges, leading to a lawsuit initiated by Zeo against BioXtek for breach of contract. Additionally, Zeo has been involved in various legal proceedings, including a lawsuit from a former Chief Science Officer regarding severance payments.
The company’s financial position remains precarious, with a working capital deficit of $1.9 million as of October 31, 2025. Zeo's management has expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for additional capital to fund operations and clinical trials. The company is exploring various financing options, including private offerings, to stabilize its financial situation and support its growth strategy.
Looking ahead, Zeo aims to leverage the opportunities presented by SB 1768 to enhance its market presence and revenue streams. The company plans to expand its sales force and develop new products while continuing to focus on regulatory compliance and clinical research to support its product offerings. However, the ongoing challenges related to competition, regulatory changes, and financial constraints will be critical factors influencing Zeo's future performance.
About Zeo ScientifiX, Inc.
Zeo Scientifix, Inc. is a clinical-stage biopharmaceutical company specializing in regenerative medicine and biologics derived from perinatal sources and blood. Its core products include extracellular vesicle therapies like Zofin and autologous biologics such as Patient Pure X. The company develops innovative treatments for degenerative diseases, aesthetic applications, and pain management, operating research labs and pursuing FDA approvals to expand its market globally.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.